Long-term outcome after venom immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 4, 2010, Pages 337-341

  Golden, David B K ^a  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

insect allergy; venom immunotherapy

Indexed keywords

BEE VENOM; TRYPTASE; VENOM; WASP VENOM;

BASOPHIL; ENZYME BLOOD LEVEL; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; LONG TERM CARE; MASTOCYTOSIS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ANIMAL; DESENSITIZATION; DRUG ADMINISTRATION; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; IMMUNOLOGY; INSECT BITE; PROCEDURES; RECURRENT DISEASE; TIME;

ANIMALS; BEE VENOMS; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; INSECT BITES AND STINGS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; WASP VENOMS;

EID: 77954658370     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833bc0ba     Document Type: Review

References (45)

1. Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157-161.
2. Muller U, Thurnheer U, Patrizzi R, et al. Immunotherapy in bee sting hypersensitivity: bee venom versus whole body extract. Allergy 1979; 34:369-378.
3. Reisman RE, Dvorin DD, Randolph CC, Georgitis JW. Stinging insect allergy: natural history and modification with venom immunotherapy. J Allergy Clin Immunol 1985; 75:735-740.
4. Bonifazi F, Jutel M, Bilo BM, et al. Prevention and treatment of Hymenoptea venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-1470.
5. Golden DB. Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 2005; 115:439-447.
6. Moffitt JE, Golden DBK, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004; 114:869-886.
7. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579-587.
8. Golden DBK, Kwiterovich KA, Addison BA, et al. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998; 101:298-305.
9. Golden DBK, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000; 105: 385-390.
10. Hamilton RG. Diagnostic methods for insect sting allergy. Curr Opin Allergy Clin Immunol 2004; 4:297-306.
11. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
12. Jutel M, Akdis M, Blaser K, Akdis CA. Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol 2005; 5:365-369. (Pubitemid 41017653)
13. Mamessier E, Birnbaum J, Dupuy P, et al. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006; 36:704-713.
14. Pereira-Santos MC, Baptista AP, Melo A, et al. Expansion of circulating Foxp3+CD25brightCD+ T cells during specific venom immunotherapy. Clin Exp Allergy 2007; 38:291-297.
15. Saverino D, Riccio AM, Rogkakou A, et al. Serum cytotoxic T lymphocyteassociated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. J Allergy Clin Immunol 2009; 123:258-260.
16. Golden DBK, Johnson K, Addison BI, et al. Clinical and immunologic observations in patients who stop venom immunotherapy. J Allergy Clin Immunol 1986; 77:435-442.
17. Golden DBK, Lawrence ID, Kagey-Sobotka A, et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992; 90:386-393.
18. Dugas-Breit S, Przybilla B, Dugas M, et al. Serum concentration of baseline serum mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010; 40:643-649.
19. Varga EM, Francis JN, Zach MS, et al. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009; 39:1353-1357.
20. Randolph CC, Reisman RE. Evaluation of decline in serum venom-specific IgE as a criterion for stopping venom immunotherapy. J Allergy Clin Immunol 1986; 77:823-827.
21. Reisman RE, Lantner R. Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venomspecific IgE to insignificant levels with patients stopped prematurely by selfchoice. J Allergy Clin Immunol 1989; 83:1049-1054.
22. Urbanek R, Forster J, Kuhn W. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 1985; 107:367-371.
23. Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993; 92:831-836.
24. Lerch E,Muller U. Long-term protection after stopping venom immunotherapy. J Allergy Clin Immunol 1998; 101:606-612.
25. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339-348.
26. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680-686.
27. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216-1220.
28. Rueff F, Przybilla B, Bilo MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase: a study of the EAACI Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-1054.
29. Kosnik M, Silar M, Bajrovic N, et al. High sensitivity of basophils predicts side effects in venom immunotherapy. Allergy 2005; 60:1401-1406.
30. Niedoszytko M, deMonchy J, vanDoormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237-1245.
31. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226-232.
32. DeOlano DG, Alvarez-Twose I, Esteban-Lopez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519-526.
33. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-535.
34. Golden DBK, Addison BI, Gadde J, et al. Prospective observations on patients who discontinue venom immunotherapy. J Allergy Clin Immunol 1989; 84:162-167.
35. Muller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702-709.
36. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108:1027-1032.
37. Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy 2003; 91:405-410.
38. Sturm G, Kranke B, Rudolph C, et al. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002; 110:928-933.
39. Oren E, Chegini S, Hamilos DL. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy. Ann Allergy Asthma Immunol 2006; 97:606-610.
40. Haugaard L, Norregaard OFH, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991; 87:699-702.
41. VanHalteren HK, vanderLinden PWG, Burgers JA, Bartelink AKM. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997; 100:767-770.
42. Golden DBK, Kagey-Sobotka A, Norman PS, et al. Outcomes of allergy to insect stings in children with and without venom immunotherapy. N Engl J Med 2004; 351:668-674.
43. Muller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337-341.
44. Oude-Elberink J, deMonchy J, Kors J, et al. Fatal anaphylaxis after a yellow jacket sting despite venom immunotherapy in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99:153-154.
45. Wagner N, Fritze D, Przybilla B, Hagedorn M. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Appl Immunol 2008; 148:162-163.